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Abstract: This review covers important anticancer and antifungal compounds reported 
from filamentous fungi and in particular from Aspergillus, Penicillium and Talaromyces. 
The taxonomy of these fungi is not trivial, so a focus of this review has been to report the 
correct identity of the producing organisms based on substantial previous in-house 
chemotaxonomic studies. 
Keywords: anticancer; polyketides; non-ribosomal peptides; terpenoids; fungi;  
natural products; taxonomy 
 
1. Introduction 
Filamentous fungi such as Aspergillus, Penicillium and Talaromyces are some of the most incredible 
chemical factories known today. Accordingly, numerous bioactives such as mycotoxins, antifungal and 
anticancer agents have been reported in the literature within the last more than 100 years [1]. Despite this 
many new compounds revealing remarkable new bioactivities are still being discovered, including 
well-known metabolites such as griseofulvin [2–5]. This, combined with the fact that large 
combinatorial libraries have not provided the anticipated number of new chemical entities explains 
why the field of natural products is currently assuming new prominence. Thus, natural products are 
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still used as scaffolds for synthetic organic chemistry, although nowadays primarily for designing 
smaller and more focused diversity oriented synthesis-derived libraries [6]. 
It has been estimated that approximately 1.5 million or likely as many as 3 million fungal species 
exist on Earth, of which only around 100,000 species have been described so far [7]. A multitude of 
new species are likely to be discovered from diverse habitats, such as tropical forest plants and soils, 
associated to insects and in the marine environment. In addition to untapped biodiversity recent 
sequencing of complete fungal genomes has revealed that many gene clusters are silent, suggesting the 
possibility for many more compounds [8]. Despite several efforts to stimulate such pathways using 
epigenetic modifiers [9,10], it is evident that we still do not know the full biosynthetic potential even 
of well studied model organisms such as Aspergillus nidulans, altogether strongly indicating Nature’s 
potential as source of new promising bioactive small molecule scaffolds. 
The renewed interest in natural product discovery is further enhanced with the new strategies  
and methodologies for fast dereplication that have been developed within the last decade.  
Thus chromatographic and spectroscopic methods are combined with database searching in for 
example Antibase, which is a comprehensive database for natural products from microorganisms [11]. 
The performance of mass spectrometers is continuously improving, including easy access to both positive 
and negative ionization spectra even during fast ultra-high-performance liquid chromatography (UHPLC). 
Altogether the use of accurate mass measurements for dereplication of unknown compounds reduces 
the number of predicted elemental compositions, ensuring that database searches are conducted with 
the fewest possible candidates [12]. The use of UV spectral information is often important in the 
dereplication process for prioritizing between the MS-generated candidates, as well as for UV-guided 
discovery of novel compounds [13,14]. 
This article reviews anticancer and often also antifungal natural products primarily produced by 
Aspergillus, Penicillium and Talaromyces. For practical reasons the compounds have been grouped 
into major biosynthetic classes, according to the biosynthetic origin of the core part of the structures, 
despite that many compounds are actually of mixed biosynthetic origin (e.g., prenylated). This review 
is broader in scope than other recent reviews only focusing on endophytes [15,16], and a strong focus 
has been on giving the correct identity of the species reported in the literature, where many may 
previously have been misidentified or names have been changed according to the 2011 Amsterdam 
Declaration on Fungal Nomenclature [17]. 
2. Polyketide-Derived Anticancer Compounds 
Polyketides represents one of the major classes of natural products of which many are biological 
active [1]. Today much is known about the enzymes involved in the biosynthesis of a huge diversity of 
both non-reduced (aromatic), partly reduced and highly reduced polyketides [8]. 
Some famous fungal polyketides with anticancer activity belong to the statin family. The statins are 
well known cholesterol synthesis inhibitors that are used in clinical treatment of hypercholesterolemia 
and cardiovascular diseases [18–21]. Moreover, members the statin family are known to have 
antifungal properties against Aspergillus spp. and Candida spp. [18,22–24]. The statin family includes 
a long list of both natural and synthetic compounds, for example the naturally derived compactin, 
lovastatin and pravastatin. The statin structure is based on a dicyclohexene ring system connected to a 
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dicyclohexene ring system connected to a side chain with a closed lactone ring or an open acid form [21]. 
The compactins are primarily produced by P. solitum and P. hirsutum [20,25] (first misidentified as  
P. brevicompactum [18] and a fungus identified as P. citrinum [19]). Another group of statins that has an 
extra methyl group attached on the dicyclohexene ring system are produced by A. terreus [26] and 
Monascus spp. [27]. Several in vitro activities of the statins have been published throughout the years. 
Reports showed that compactin (Figure 1a) inhibited acute myeloid leukemia (AML) cells with a full 
inhibitory concentration (IC100) of 2.6 µM [28]. The analogs lovastatin (Figure 1b) and simvastatin 
(Figure 1c) have been shown to be even more potent. 
Figure 1. Statins: (a) Compactin, (b) Lovastatin and (c) Simvastatin. 
 
Lovastatin and the synthetic simvastatin selectively inhibited colony growth of primary AML cells 
with 75%–95% effectiveness. No effect was seen on normal bone marrow [29]. The more recent 
reported activities includes reduction of proliferation by lovastatin in four lung cancer cell lines with 
median inhibitory concentration (IC50) values between 1.5 and 30 µM [30]. In 2010 it was shown that 
lovastatin induced apoptosis in ten ovarian cancer cell lines tested, with IC50 values between 2 and  
39 µM [31], and recently lovastatin was found to inhibit breast cancer MCF-7, liver cancer HepG2, 
and cervical cancer HeLa cell lines with IC50 values of 0.7, 1.1 and 0.6 µg/mL, respectively [32]. 
Simvastatin inhibited two lung cancer, three melanoma, and four breast cancer cell lines with IC50 
values between 0.8 and 5.4 µM and induced apoptosis with reduced tumor growth in hepatic cancer 
cells [33,34]. Encouraged by these results simvastatin has entered clinical trials as an anticancer drug [35]. 
The three small polyketides terrein, brefeldin A, and asperlin are examples of well-known 
metabolites that a couple of decades after they were discovered were shown to exhibit novel anticancer 
activities. The small antifungal [36] polyketide terrein (Figure 2a) produced by A. terreus has been 
known since 1935 [37]. Almost 80 years later it was found that terrein inhibits breast cancer by 
induction of apoptosis with an IC50 value of 1.1 nM in MCF-7 cell line. That makes terrein 100-fold 
more potent than taxol against this cell line. Additionally terrein was found active against pancreatic 
and liver cancer cell lines PANC-1 (IC50 9.8 µM) and HepG2 (IC50 66.8 µM) [38]. 
Figure 2. Small polyketides: (a) Terrein, (b) Brefeldin A, and (c) Asperlin. 
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Brefeldin A (Figure 2b), another small antifungal [39,40] polyketide isolated in 1958 from  
P. brefeldianum [41] was identified almost 40 years later as inducer of apoptosis in leukemia (HL-60 
and K-582), colon (HT-29), prostate (DU-145), cervical (KB and HeLa), breast (MCF-7 and BC-1), 
and lung (SPC-A-1 and NCI-H187) cancer cell lines [42–45]. The inhibiting effect of brefeldin A was 
demonstrated with IC50 values 35.7 nM (HL-60), 32 nM (KB), 6.4 nM (HeLa), 7.1 nM (MCF-7),  
40 nM (BC-1), 6.3 nM (SPC-A-1), and 110 nM (NCI-H187) [44,45]. 
Asperlin (Figure 2c) was isolated from A. nidulans in 1966 [46]. In 2011 it was discovered that 
asperlin reduces cell proliferation and induce G2/M cell cycle arrest in the human cervical carcinoma 
HeLa cell line [47]. 
Filamentous fungi are known to produce anticancer polyketides with different spiro ring structures. 
One of the more well-known is the antifungal [48,49] compound griseofulvin (Figure 3a) from  
P. griseofulvum [50]. Griseofulvin was introduced commercially in 1965 and first considered for 
cancer treatment in 1973 [49,51]. Later it was shown to induce cell proliferation and mitosis in the 
human cervical cancer cell line HeLa with an IC50 value of 20 µM, as well as it inhibits centrosomal 
clustering in human squamous cancer SCC-114 cell line with an IC50 value of 35 µM [2,3].  
The synthetic analog GF-15 increased the inhibitory effect of centrosomal clustering in SCC-114 cells  
25-fold with an IC50 value of 0.9 µM [5]. It was further shown that combined treatment of griseofulvin 
and the cancer chemotherapeutic agent nocodazole in vivo improved the effect of nocodazole and 
arrested tumor growth in mice infected with COLO 205 tumors [4]. 
Other examples of fungal anticancer polyketides with spiro ring structures are sequoiamonascin A 
(Figure 3b) and B from A. parasiticus [52]. Sequoiamonascin A demonstrated selective cytotoxicity 
against six leukemia cell lines and two melanoma cell lines with a median growth inhibitory (GI50) 
log10 value of -6.00 [52]. Furthermore, sequoiamonascin A shows cytotoxic activity against breast 
cancer MCF-7, lung cancer NCI-H460 and central nervous system (CNS) cancer SF-268 cell lines 
where cell growth can be reduced to 1%–2% when treated with 10 µM sequoiamonascin A [52]. 
Figure 3. Spiro compounds: (a) Griseofulvin, and (b) Sequoiamonascin A. 
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A group of fungal γ-pyrones were found to have activity against cancer. An example of these is the 
antifungal [48,49] 3-O-methylfunicone (Figure 4a) produced by T. pinophilus (originally published as 
P. pinophlium) [1,48]. It induced apoptosis and affects cell proliferation in various cancer cell lines 
including HeLa, MCF-7, A-375P and A-375M [50–53]. Another structurally related compound is 
penisimplicissin (Figure 4b) isolated from T. pinophilus (originally published as P. simplicissimum) [54]. 
It displayed selective cytotoxicity towards leukemia HL-60 and CCRF-CEM cell lines with log10 GI50 
−6.7 and −5.8, respectively [55]. 
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Figure 4. γ-Pyrones: (a) 3-O-Methylfunicone and (b) Penisimplicissin. 
 
A group of more than 20 closely related azaphilones, namely the antifungal [56] chaetomugilin family, 
has been isolated within the last five years from marine fish-derived Chaetomium globosum [57–64].  
The chaetomugilins C, I, P and 11-epichaetomugilin I (Figure 5) showed significant inhibition of two 
human leukemia P-388, HL-60 and one murine leukemia L-1210, as well as human cervical cancer cell 
line, KB with 11-epichaetomugilin I as the more potent with IC50 values of 0.7 µM (P-388), 1.0 µM 
(HL-60), 1.6 µM (L-1210), and 1.2 µM (KB) [62]. 
Figure 5. 11-Epichaetomugilin I. 
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The fungal metabolite norsolorinic acid (Figure 6a) with a tricyclic structure is produced by  
A. parasiticus and A. nidulans [65–68]. Norsolorinic acid selectively induced cell cycle arrest in G0/G1 
phase of the cell cycle and consequently induced apoptosis in human bladder cancer T-24 and human 
breast cancer MCF-7 with IC50 values of 10.5 and 12.7 µM, respectively [67,68]. 
Figure 6. (a) Norsolorinic acid and (b) Austocystin D. 
 
Austocystin D (Figure 6b) was isolated from A. pseudoustus [69] in 1974 (originally misidentified 
as A. ustus [70]). Austocystin D was shown to selectively inhibit growth of human colon carcinoma 
LS174T cells in mice and tumor cell lines that overexpress the multidrug resistance-associated protein [71]. 
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Additionally, austocystin D inhibited a number of cancer cell lines: SR (leukemia, GI50 16 nM),  
U-87 (brain, GI50 4946 nM), MCF-7 (breast, GI50 < 1 nM), MDA-MB-231 (breast, GI50 549 nM),  
PC-3 (prostate, GI50 3 nM), SW-620 (colon, GI50 27 nM), HCT-15 (colon, GI50 42 nM), and MX-2 
(uterine, GI50 3358 nM) [72]. Although, displaying diverse activities towards many types of cancer 
lines, austocystin D never entered clinical trials due to a low safety window [71]. 
The two epimers chloctanspirone A and B (Figure 7a) are probably produced by P. chrysogenum or 
P. rubens [73,74] (originally published incorrectly as P. terrestre [75]). Chloctanspirone A and B were 
the first chlorinated sorbicillinoids isolated from a natural source and the first to be identified with 
their very unique ring structure. Chloctanspirone A was the more active analog and inhibited human 
leukemia HL-60 and lung cancer cell line A-549 cell lines with IC50 values of 9.2 and 39.7 µM, 
respectively [76]. Chloctanspirone B however, only showed moderately or no activity against the same 
cell lines. Interestingly, the two precursors terrestrols K and L (Figure 7b) that contain the epicenter, 
which dissociates chloctanspirone A from B were inactive. This points to the conclusion that the 
cyclohexenone moiety has an impact on the activity though it is not the pharmacophore [76]. 
Figure 7. (a) Chloctanspirone A, B and (b) Precursors terrestrols K, L. 
 
A group of around 20 p-terphenyls were isolated from A. candidus and found to be cytotoxic against 
the human cervical cancer cell line HeLa [77]. Thirty years later a new group of prenylated-p-terphenyls, 
called prenylterphenyllins (Figure 8a), terprenins (Figure 8b), and prenylcandidusins (Figure 8c) were 
isolated from A. candidus and A. taichungensis [78,79]. The activity of these compounds were studied 
against lung cancer cell line A-549, human leukemia cell lines HL-60 and P-388, and human 
epidermoid cancer cell lines KB3-1 [78,79]. Prenylterphenyllin A was found to be the more active 
against A-549 and HL-60 with IC50 values of 8.3 and 1.5 µM, respectively [79], whereas  
4′′-deoxyisoterprenin displayed higher activity towards KB3-1 with an IC50 value of 6.2 µM [78], and 
finally prenylcandidusin B showed higher activity against P-388 with an IC50 value of 1.6 µM [79]. 
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Figure 8. Prenylterphenyllins: (a) Prenylterphenyllin A, (b) 4′′-Deoxyisoterprenin,  
and (c) Prenylcandidusin B. 
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In 2011 five new di- and tricitrinols were added to the known citrinin family from P. citrinum [80]. 
All five of them showed cytotoxic activity against human leukemia HL-60, colon cancer HCT-116, 
and cervical cancer KB cell lines. The more potent was tricitrinol B (Figure 9), with IC50 values of 3.2, 
4.8 and 3.9 µM, respectively [80]. 
Figure 9. Tricitrinol B. 
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The class of perylenequinones has been used for centuries in Chinese herbal medicine, but fungal 
production of several perylenequinones has likewise been reported [81]. The calphostins were isolated 
from Cladosporium cladosporioides and shown to inhibit cervical cancer HeLa-S3 and breast cancer 
MCF-7 cell lines. Most potent was calphostin C (Figure 10a) with IC50 values of 0.23 and 0.18 µM, 
respectively [82]. Furthermore, calphostin C induced apoptosis in acute lymphoblastic leukemia [83]. 
The hypocrellins, another branch, of the perylenequinone family was isolated from Hypocrella 
bambusae, originally published incorrectly as Shira bambusicola [84,85]. Hypocrellin D was one of 
the more potent analogs and inhibited liver (Bel-7721) and lung (A-549 and Anip-973) cancer cell 
lines, with IC50 values, 1.8, 8.8, 38.4 µg/ml, respectively [85]. Additionally, the hypocrellins had a 
photodynamic effect on a wide range of tumor cell lines. Due to their insolubility in water several 
analogs have been synthesized to improve the pharmacokinetics and drug delivery. Two of the more 
successful analogs were carboxylate salt derivatives of hypocrellin B (Figure 10b) with increased 
water solubility and activity against human breast cancer MCF-7 when photodynamic therapy was 
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used [81,86]. In 2012 a new group of perylenequinones called the phaeosphaerins were isolated from 
Phaeosphaeria sp. with phaeosphaerin B (Figure 10c) as the more potent against prostate PC-3,  
DU-145, LNCaP cancer cell lines with IC50 values of 2.4 µM, 9.5 µM and 2.7 µM, respectively [87]. 
Figure 10. Perylenequinones: (a) Calphostin C, (b) Hypocrellin B and (c) Phaeosphaerin B. 
 
3. Nitrogen-Containing Anticancer Compounds 
Fungal nitrogen containing compounds represent another large group of natural products, of which 
many have famous bioactivities. In general these types of compounds incorporate amino acid building 
blocks into often complex heteroaromatic compounds such as diketopiperazines, quinazolines and 
benzodiazepines [1]. Often these compounds are referred to as alkaloids, due to their basic nature, 
when containing primary, secondary or tertiary amine functionalities. However, compounds only 
containing amide bonds, that are essentially neutral, are often also referred to as alkaloids. In recent 
years it has become clear that many nitrogen containing compounds are biosynthesized by 
multifunctional enzymes (non-ribosomal peptide synthases, NRPS) with modular arrangements 
comparable to that seen for some polyketide synthases. In such contexts these compounds are usually 
referred to as non-ribosomal peptides (NRPs) even though they are also called alkaloids [88]. In the 
following section no attempt has been made to differentiate between the different naming of the 
numerous amino acid-derived metabolites. 
The antifungal [89] xanthocillin X (Figure 11) was first isolated from Dichotomomyces albus 
ascribed to D. cejpii [90], but is produced by P. chrysogenum as well [1]. In 1968 xanthocillin X was 
found active against a Ehrlich ascites carcinoma-mouse strain with median lethal dose (LD50) of  
40 mg/kg [91]. Approximately 40 years later it was shown that xanthocillin X inhibited leukemia  
K-562, human cervical cancer HeLa, breast cancer MCF-7 and MDA-MB-231, liver cancer HepG2, 
lung cancer NCI-H460, and prostate cancer DU-145 cell lines with IC50 values between 0.4 and  
12 µg/ml [89,92]. Two structural analogs named BU-4704 and xanthocillin X di-methoxy were found 
more potent than xanthocillin X. Instead of the two hydroxy groups BU-4704 contains a methoxy and 
a sulfonic acid group and xanthocillin X di-methoxy contains two methoxy groups. BU-4704 inhibited 
human colon HCT-116 and murine melanoma B16-F10 with IC50 values of 0.6 and 4.3 µg/mL, 
respectively [93]. Xanthocillin X di-methoxy inhibited HepG2, MCF-7 and KB cancer cell lines with 
IC50 values of 0.18, 0.38 and 0.44 µg/mL, respectively [94]. 
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Figure 11. Xanthocillin X. 
 
Asperphenamate (Figure 12) was first isolated from A. flavipes [95] and later found to be produced 
by several of Penicillium spp. as well [96]. Asperphenamate displayed moderate cytotoxic activity 
against several cancer cell lines [97]. Due to the low activity and a low water solubility 
asperphenamate was used as a lead for synthetic structurally isomers. It was found that the (R,S) 
stereoisomers were more potent than the (S,R) stereoisomers [98]. The more active asperphenamate 
derivate was N-benzoyl-O-(N′-(1-benzyloxycarbonyl-4-piperidiylcarbonyl)-D-phenylalanyl)-D-phenyl- 
alaninol (BBP). BBP was approx. 20-fold more active than asperphenamate against breast cancer 
(MCF-7, T47D and MDA-MB231), hepatic (BEL-4702), lung (A-549), and cervical (HeLa) cancer as 
well as leukemia (HL-60) cell lines, with IC50 values between 3.0 and 18.3 µM [99]. 
Figure 12. Asperphenamate. 
 
Cyclic di-peptides called diketopiperazines are in general known as cell cycle inhibitors of the 
G2/M phase [100]. Tryptophan/proline diketopiperazines covers the compound groups 
fumitremorgins, stephacidins, notoamides, tryprostatins, etc. This group of compounds is produced by 
a long range of Aspergilli [101–110]. The fumitremorgins are produced by A. fumigatus and  
A. fischeri [101–103,111]. Fumitremorgin C (Figure 13a) was found active against human leukemia  
P-388 with an ED50 value of 3.9 µg/mL and the analog 12,13-dihydroxyfumitremorgin C has 
antiproliferative effects on human leukemia U-937 and human prostate cancer PC-3, with IC50 values 
of 1.8 and 6.6 µM, respectively [111,112]. Furthermore fumitremorgin C was specifically and potently 
cytotoxic against multi-drug resistant breast- and colon cancer [113,114]. 
Two other tryptophan/proline diketopiperazines are stephacidin A (Figure 13b) and B produced by 
A. ochraceus and A. westerdijkiae [106,107]. Stephacidin B is the dimeric form of stephacidin A and 
was approximate 10-fold more potent. Stephacidin B exhibited inhibitory effect on prostate, ovarian, 
colon, breast and lung cancer cell lines with IC50 values between 0.06 and 0.4 µM [106]. 
The notoamides (Figure 13c) produced by A. amoenus are close analogs to the stephacidins, but 
with a spiro ring structure [115]. Contrary to the stephacidins the notoamides only showed low to 
moderate inhibition of two leukemic cell lines with IC50 values 22–52 µg/mL [116]. 
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Figure 13. Tryptophan/proline diketopiperazines: (a) Fumitremorgin C, (b) Stephacidin A, 
(c) Notoamide A, (d) 18-Oxotryprostatin A and (e) Spirotryprostatin E. 
 
Finally, the tryprostatins (Figure 13d) and spirotryprostatins (Figure 13e) isolated from A. fumigatus 
where found active against lung (NCI-H-522 and A-549), breast (MCF-7) and prostate (PC-3) cancer 
as well as leukemia (HL-60 and MOLT-4). The more potent analogs were Ds1-tryprostatin B with GI50 
values of 15.8 µM (NCI-H-522), 15.9 µM (MCF-7), and 11.9 µM (PC-3) and 18-oxotryprostatin A 
with an IC50 value of 1.3 µM (A-549) [108,110]. Spirotryprostatin E was the more potent of the 
spirotryprostatins, with IC50 values of 3.1 µM (MOLT-4), 2.3 µM (HL-60) and 3.1 µM (A-549) [109]. 
Other diketopiperazines originating from histidine are phenylahistin (Figure 14a) and aurantiamine 
(Figure 14b). Phenylahistin was first isolated from A. ustus in 1997 as a mixture of enantiomers [117]. 
(−)-Phenylahistin was more active than (+)-phenylahistin against dermal (A-431), lung (A-549), ovary 
(HeLa), leukemia (K-562 and P-388), breast (MCF-7), CNS (TE-671) and colon (WiDr) cancer cell 
lines with IC50 between 0.18 and 3.7 µM [118]. A synthetic analog plinabulin (NPI-2358) displays very 
potent activity against human prostate carcinoma cell line DU-145 and has now entered phase II 
clinical trials [119]. Recently, more than 60 synthetic analogs of plinabulin have been designed and 
synthesized. The more active analog with a benzoyl group coupled on the phenylalanine unit was  
10-fold more active than plinabulin with an IC50 value of 1.4 nM [119]. The activity of phenylahistin 
was also compared to the diketopiperazine aurantiamine and other synthetic analogues [120], 
originally isolated by Larsen et al. [121]. 
Figure 14. (a) Phenylahistin and (b) Aurantiamine. 
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Another group of diketopiperazines with anticancer activity contain a di-sulfide bridge in the 
diketopiperazine ring. One of them the antifungal, immunosuppressive and antimicrobial compound 
gliotoxin (Figure 15a) that was isolated from A. fumigatus, and D. cejpii [122–124]. Already in 1947 
the anticancer activity of gliotoxin was suggested and in 2004 it was found that gliotoxin was a very 
potent inhibitor of six breast cancer cell lines with IC50 values between 38 and 985 nM [125,126]. In 
2012, gliotoxin was found active against human leukemia U-937 and human prostate cancer PC-3 cell 
lines with IC50 values of 0.2 and 0.4 µM, respectively [112]. 
Figure 15. Diketopiperazines with a di-sulfide bridge: (a) Gliotoxin, (b) Emestrin A and 
(c) Acetylapoaranotin. 
 
Another diketopiperazine with a di-sulfide bridge is the antifungal [127] compound emestrin A 
(Figure 15b) that was isolated from Emericella striata, now called A. striatus [128]. Emestrin A 
inhibits human leukemia (HL-60) with an IC50 value of 83.5 nM [129]. Eight structural analogs of 
emestrin A were isolated from Cladorrhinum sp. and found to have strong antiproliferative effects on 
the human prostate DU-145 cancer cell line with an IC50 value of 9.3 nM for the more potent emestrin 
C. Furthermore, it was proven that the activity decreased when the macro cyclic ring was opened and 
the polysulfide bridge in the diketopiperazine was absent [130]. 
Recently, a new diketopiperazine with a di-sulfide bridge named acetylapoaranotin (Figure 15c) 
produced by a marine Aspergillus sp. was discovered and found active against colon (HCT-116), 
gastric (AGS), lung (A-549), and breast (MCF-7) cancer cell lines with IC50 values of 13.8, 12, 2 and 
10 µM, respectively [131]. 
The peptide leucinostatin A (Figure 16) was first isolated in 1973 from Purpureocillium lilacinum 
(originally published as Penicillium lilacinum or Paecilomyces lilacinus) [132,133]. It was found 
active against a number of fungi and Gram-positive bacteria, as well as Ehrlich solid carcinoma of 
mice with an ED50 value of 1.6 mg/kg [132,134]. Furthermore leucinostatin A inhibited a long range of 
breast, melanoma, lung, ovary, colon and laryngeal cancers as well as eight leukemia cell lines with 
IC50 values between 4 nM and 12 µM [132,135,136]. Leucinostatin A inhibited growth of prostate 
cancer DU-145 cells in vitro and in vivo [137]. A natural analog leucinostatin A β di-O-glycoside 
displayed active against breast cancer BT-20 cell line, though not as potent as leucinostatin A [138]. 
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Figure 16. Leucinostatin A. 
 
4. Terpenoid-Derived Anticancer Compounds 
Terpenoids form a third large and structurally diverse biosynthetic family of natural products 
derived from C5 isoprene units. Until now active anticancer terpenoids mostly belong to the  
sesqui- or diterpenoids [15]. 
Taxol, also known as paclitaxel (Figure 17), is one of the best known anticancer drugs produced by 
fungi, though it originally was isolated from the bark of yew tree Taxus brevifolia [139]. Clinical 
development of taxol was delayed due to problems with production of large enough quantities of the 
compound. This problem was solved 20 years later when it was demonstrated that taxol was also 
produced by the fungus Taxomyces andreanea [140] and later including P. raistrickii [141]. 
Figure 17. Taxol. 
 
Taxol was approved as anticancer drug against a wide range of tumors in the 1990s and is the first 
billion dollar drug against cancer [142,143]. Taxol functions by inducing cell cycle arrest in G2/M 
phase as well as apoptosis through a unique mode-of-action by promotion and stabilization of tubulin 
polymerization [144]. Today, taxol is routinely used to treat ovarian, breast and lung tumors as well as 
Kaposi’s sarcoma [145]. Besides its anticancer activity taxol displays antifungal activity as well [146]. 
Many sesquiterpenes have been found active against cancer. Two of these are the drimane 
sesquiterpenes fudecadione A and B (Figure 18a) that were isolated in 2011 from Penicillium sp. BCC 
17468. Fudecadione A was found active against human lung cancer NCI-H187, human breast cancer 
MCF-7, and human oral epidermoid carcinoma KB cell lines, with IC50 values of 24.9, 12.6 and  
22.6 µM, respectively. Fudecadione B, on the other hand, was inactive against all three cancer call 
lines [147]. The activity of the two compounds suggests that the pharmacophore is located around the 
carbon at position 13, where fudecadione B is more branched [147]. 
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Figure 18. (a) Fudecadione A, (b) Terrecyclic acid A and (c) a novel unnamed  
chloro-trinoreremophilane sesquiterpene. 
 
Another active sesquiterpene is the antifungal terrecyclic acid A (Figure 18b), which was isolated 
from A. terreus in 1986 [148]. Terrecyclic acid A exhibit cytotoxic activity against human lung cancer 
NCI-H460, human breast cancer MCF-7, and human CNS cancer SF-268 cell lines with IC50 values of 
10.6, 24.1 and 14.7 µM, respectively, and against leukemia in mice P-388 with LD50 values of  
63–125 mg/kg [148,149]. 
In 2013 a novel and as yet unnamed chlorotrinoreremophilane sesquiterpene (Figure 18c) was isolated 
from Penicillium sp. PR19N-1 [150]. This novel sesquiterpene exhibited cytotoxic activity against human 
leukemia HL-60 and lung cancer A-549 cell lines with IC50 values of 11.8 and 12.2 µM, respectively [150]. 
A large group of mycotoxins called the trichothecenes cover more than 150 analogs and are mainly 
produced by a number of Fusarium spp. [151]. All the trichothecenes contain a sesquiterpenoid ring 
structure with an epoxide. The epoxide is often responsible for the cytotoxic activity by binding to the 
60S ribosomal subunit in eukaryote cells thereby inhibiting protein synthesis [152,153]. Many of the 
trichothecenes exhibit cytotoxic activity against both fungi and cancer cell lines [154–156]. One of the 
more potent is AETD (Figure 19a) that inhibits HL-60, U-937, HeLa, MCF-7 and Hep-G2 cell lines 
with IC50 values of 10, 22, 45, 53 and 170 nM [157]. Other bioactive groups are the roridins where a 
macrocyclic ring is connected to the sesquiterpenoid unit. One of the more active compounds of this 
group is 12′-hydroxyroridin E (Figure 19b), which inhibits leukemia L-1210 with an IC50 value of  
0.2 µM [158]. Another trichothecene called anguidine even entered clinical trials against cancer,  
but did not progress beyond phase II due to a lack of therapeutic efficacy [152,159]. 
Figure 19. Trichothecenes (a) AETD and (b) 12′-Hydroxyroridin E. 
 
Wentilactone A and B (Figure 20a) were isolated from A. wentii in 1980 [160]. In 2012 it was 
reported that wentilactone B induced apoptosis and inhibited proliferation in human hepatoma cancer 
cell line SMMC-7721, with an IC50 value of 19 µM [161]. 
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Figure 20. (a) Wentilactone B and (b) Wortmannin. 
 
The antifungal compound wortmannin (Figure 20b) is produced by T. wortmannii originally 
published as P. wortmannii [162] or a related species. Wortmannin inhibit the activity of leukemia  
HL-60 and K-562 cell lines with IC50 values of 30 and 25 nM, respectively [163,164], including the breast 
cancer MCF-7 cell line that was inhibited by 51.3% after 48 h with a concentration of 25 nM [165].  
In human pancreatic cancer cells lines PK1 and PK8 wortmannin induces apoptosis both in vitro and  
in vivo [166,167]. Finally, wortmannin has been shown to inhibit proliferation in lung cancer cell lines 
KNS-62 and Colo-699 both in vitro and in vivo, with IC50 values between 100 and 200 nM [168]. 
The ophiobolins are sesterterpenes mainly isolated from the fungal genus Bipolaris [169,170], but 
are also found in Aspergillus [171], Sarocladium [172,173], and Drechslera [174]. Isolation of 
ophiobolins from Aspergillus spp. misidentified as A. ustus were later ascribed to the three different 
species: A. calidoustus, A. insuetus, and A. keveii from the Aspergillus section Usti [69]. Ophiobolin A 
(Figure 21) exhibit inhibitory activity against cancer cell lines includes lung cancer A-549, colon 
cancer HT-29, melanoma Mel-20, leukemia P-388, and ovarian cancer OVCAR-3 with IC50 values of 
0.1, 0.1, 0.1, 0.06 and 0.3 µM, respectively [175,176]. In 2012 the novel ophiobolin O was discovered and 
it was found to inhibit breast cancer MCF-7 and leukemia P-388 cell lines with IC50 values of 17.9 and 
4.7 µM, respectively [177,178]. Most recently in 2013 the novel 3-anhydro-6-hydroxyophiobolin A 
was isolated and found active against lung cancer (HepG2) and leukemia (K-562) cell lines with  
IC50 values of 6.5 and 4.1 µM, respectively [179]. Besides anticancer activity the ophiobolin family 
show antifungal activity against a wide range of fungi [180,181]. 
Figure 21. Ophiobolin A. 
 
5. Anticancer Natural Products of Mixed or Unresolved Biosynthetic Origin 
Filamentous fungi are capable of producing secondary metabolites of mixed biosynthetic origin. 
This includes both compounds such as meroterpenoids that comprise a huge class of compounds that 
integrate a polyketide part with a terpenoid part [182], in addition to the cytochalasins [183] and 
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chaetoglobosins that are biosynthesized by incorporation of amino acids into a core polyketide part. 
The cytochalasins contains a phenylalanine coupled to the polyketide chain where the chaetoglobosins 
have an tryptophan moiety [183,184]. Both the cytochalasins and the chaetoglobosins exhibit 
antifungal activities against a broad range fungal species [56,185,186]. The cytochalasins are produced 
by many fungal genera including Aspergillus, Hypoxylon, Metarrhizium, Zygosporium, Hypocrella and 
Phoma [90,187–190]. Many of the cytochalasins have shown inhibitory activities towards lung cancer 
A-549. One of the more potent is cytochalasin E (Figure 22a) which inhibited human ovarian  
A-2780S, human colon HCT-116 and SW-620, and lung A-549 cancer as well as human leukemia  
P-388 with IC100 values of 0.02, 1.0, and 0.2 µg/ml and IC50 values of 0.006 and 0.09 µM,  
respectively [191,192]. 
Figure 22. (a) Cytochalasin E and (b) Chaetoglobosin B. 
 
The chaetoglobosins were originally isolated from Chaetomium globosum in 1973 [184]. Several 
chaetoglobosins have been isolated over the years from P. discolor and P. expansum among others [1] 
and many of them showed activity against cancer cell lines. Of the more potent ones was 
chaetoglobosin B (Figure 22b) that inhibited human breast BC cancer cell line with an IC50 value of 
3.0 µM [193] and chaetoglobosin D that inhibited adenocarcinoma KKU-100 and KKU-OCA17 
cancer cell lines with IC50 values of 3.4 and 12.2 µM, respectively [193]. Chaetoglobosin U showed 
activity as well against KB tumor cell line with an IC50 value of 16.0 µM [194], and chaetoglobosin X 
with activity against murine hepatic cancer H-22 cell line with an IC50 value of 7.5 µM [195]. 
Another group of compounds with mixed a biosynthetic pathway are the pseurotins (Figure 23) 
containing phenylalanine coupled to a polyketide and with a spiro ring structure. The pseurotins were 
first isolated from the bacteria Pseudeurotium ovalis and later from the fungus A. fumigatus [196,197]. 
In 2012 four pseurotin analogs were proven active against a human breast cancer cell line MCF-7 with 
the more active pseurotin D inhibiting MCF-7 with an IC50 value of 15.6 µM [198]. 
Figure 23. Pseurotin A. 
 
The γ-pyridone alkaloids, penicidone A–C (Figure 24a) were isolated from an endophytic 
Talaromyces sp. The biosynthesis of penicidones probably happens through the polyketide pathway 
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similar to penisimplicissin (Figure 24b), but with a unique introduction of nitrogen [199]. The 
penicidones were showed to be active against human colon cancer SW1116, human AML (K-562), 
and human cervical cancer (KB and HeLa) cell lines with penicidone B being the more potent analog. 
Penicidone B inhibited the four cancer cell lines with IC50 values of 54.2 µM (SW1116), 21.1 µM  
(K-562), 29.6 µM (KB), and 35.2 µM (HeLa) [199]. Two other γ-pyridone alkaloids called 
penicinoline (Figure 24b) and methylpenicinoline were isolated from an endophytic Penicillium sp. 
and Auxarthron reticulatum in 2010 and 2011, respectively [200,201]. Penicinoline and  
methylpenicinoline were shown to inhibit the lung cancer HepG2 cell line with IC50 values of 13.2 and 
11.3 µM, respectively [202]. 
Figure 24. (a) Penicidone B and (b) Penicinoline. 
 
Communesins are fungal metabolites produced in P. marinum, P. expansum, P. buchwaldii and  
P. rivulorum [96,203–205]. The group is of highly mixed biosynthetic origin with structures 
combining a nitrogen-containing part, a polyketide chain and isoprene. Communesin B (Figure 25) 
displays the highest activity of them all against leukemia P-338, U-937, THP-1, NAMALWA,  
MOLT-3 and SUP-B15 cell lines with ED50 values of 0.5, 10.4, 11.4, 9.9, 8.1 and 7.2 µg/mL, 
respectively [206,207]. 
Figure 25. Communesin B. 
 
The antibiotic compound fumagillin (Figure 26a) has been one of the more potent and interesting 
compounds associated with anticancer activity produced by fungi. Fumagillin, classified as a 
meroterpenoid, was first isolated from A. fumigatus in 1951 [208] and further produced by  
P. scabrosum [209]. The antitumor activity of fumagillin is caused by its potent angiogenesis-inhibiting 
effect. Unfortunately, fumagillin had some unpleasant side effects and consequentially investigations 
into structural analogs have been conducted [210]. The synthetic fumagillin analog TNP-470 (Figure 26b) 
contains an amine and chlorine in the side chain, which led to a highly increased  
angiogenesis—inhibiting effect. Furthermore, TNP-470 is less toxic to normal cells compared to 
fumagillin [210,211]. In vitro and in vivo tests showed that TNP-470 inhibited tumor growth in 
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prostate (PC-3) and breast cancer (MDA-MB-231). TNP-470 entered preclinical trails in 1992 and 
phase I and II in 2000 but did not progress into phase III, due to a very short systemic half-live and 
observed neurotoxicity in patients [212–214]. Recently, in 2013, a novel natural fumagillin analog 
namely ligerin (Figure 26c) was isolated from a marine-derived Penicillium sp.[215]. Ligerin inhibited 
lung cancer POS1 cell line with an IC50 value of 117 nM [215]. 
Figure 26. (a) Fumagillin, (b) Synthetic analog TNP-470 and (c) Ligerin. 
 
A strain so far identified as Talaromyces purpurogenus (earlier P. purpurogenum) is known to produce 
another group of meroterpenoids namely purpurogemutantin (Figure 27a), purpurogemutantidin  
(Figure 27b), and the known antifungal macrophorin A (Figure 27c) [216,217]. All three compounds 
inhibit human leukemia K-562 and HL-60, human cervical cancer HeLa, human gastric 
adenocarcinoma BGC-823 and human breast cancer MCF-7 cell lines. Purpurogemutantidin (Figure 27a) 
was the more potent, with IC50 values of 0.9, 2.4, 16.6, 31.0, and 26.3 µM, respectively. The only 
exception is macrophorin A that displayed higher activity towards the HL-60 cell line with an IC50 
value of 0.9 µM [216]. 
Figure 27. (a) Purpurogemutantin, (b) Purpurogemutantidin and (c) Macrophorin A. 
 
Botryodiplodin (PSX-1), a small antifungal [218] compound of unresolved biosynthetic origin 
(Figure 28), was isolated from T. stipitatus (originally named P. stipitatum) [219] and exhibits activity 
against Ehrlich ascites carcinoma, leukemia L-5178, Sarcoma 37, and cervical cancer Hela cell lines 
with a median effective dose (ED50) values of approximately 1 µg/mL [219,220]. 
Figure 28. Botryodiplodin (PSX-1). 
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The atpenins A4, A5 and B (Figure 29) of unresolved biosynthetic pathway were first isolated from 
P. atramentosum in 1988 and shown to possess antifungal activities [221]. Twenty years later the first 
three atpenins were isolated again from the same fungi along with two new analogs, NBRI23477 A 
and B [222]. The activities of the five atpenins were examined individually against human prostate 
cancer cell line DU-145 and in a stromal co-cultured assay. Growth of the DU-145 cells was inhibited 
more effectively in the co-cultured setup, with atpenin A5 being the more potent analog with an IC50 
value of 0.02 µg/mL [222]. All the reviewed compounds are summarized in Table 1 with their 
individual organisms of origin, biosynthetic pathways, target cancer cells, IC50 (if available), and 
whether the compounds exhibit antifungal activity too. 
Figure 29. Atpenin A5. 
 
Table 1. List of fungal anticancer natural products primarily produced by Aspergillus, 
Penicillium and Talaromyces summarizing producing organisms, biosynthetic origin, target 
cancer cells, IC50 (if available), and if the compounds exhibit antifungal activity. 
Species (original 
published) Compound Type Target cell IC50 Anti-fungal (+/−) 
T. pinophilus [1] 
(P. pinophilum [48]) 
3-O-methylfunicone 
[50–53] 
Polyketide HeLa - + [48,49] 
MCF-7 - 
A-375P - 
A-375M - 
A. nidulans [46] Asperlin [47] Polyketide HeLa - − 
A. flavus [95] 
Penicillium spp. [96] 
Asperphenamate NPR - - − 
A. flavus [95] 
Penicillium spp. [96] 
BBP [99] NPR MCF-7 3.0 µM 
T47D 4.7 µM 
MDA-MB231 5.2 µM 
BEL-4702 12.7 µM 
A-549 15.1 µM 
HeLa 17.0 µM 
HL-60 18.3 µM 
Aspergillus sp. [131] Acetylapoaranotin 
[131] 
NPR HCT-116 13.8 µM − 
AGS 12 µM 
A-549 2 µM 
MCF-7 10 µM 
P. atramentosum [222] Atpenin A5 [222] Unresolved 
biosynthetic 
origin 
DU-145  
(co-culture) 
0.02 µg/mL + [221] 
A. puniceus [69] 
A. turkensis [69] 
A. pseudoustus [69] 
A. ustus [70] 
Austocystin D [71,72] Polyketide SR 16 nM (GI50) − 
U-87 4946 nM (GI50) 
MCF-7 <1 nM (GI50) 
MDA-MB-231 549 nM (GI50) 
PC-3 3 nM (GI50) 
SW-620 27 nM (GI50) 
HCT-15 42 nM (GI50) 
MX-2 3358 nM (GI50) 
P. brevicompactum [20] 
P. paneum [223] 
T. stipitatus [1] 
(P. stipitatum [220]) 
Botryodiplodin 
[219,220] 
Unresolved 
biosynthetic 
origin 
EAC 0.6 µg/mL (ED50) + [218] 
L-5178 0.8 µg/mL (ED50) 
Sarcoma 37 1.5 µg/mL (ED50) 
HeLa 2.0 µg/mL (ED50) 
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Table 1. Cont. 
Species (original 
published) Compound Type Target cell IC50 Anti-fungal (+/−) 
P. brefeldianum [39] Brefeldin A [42–45] Polyketide HL-60 35.7 nM + [39,40] 
KB 32 nM 
HeLa 6.4 nM 
MCF-7 7.1 nM 
SPC-A-1 3.6 nM 
BC-1 40 nM 
NCI-H187 110 nM 
Cladosporium 
cladosporioides [82] 
Calphostin C [82,83] Polyketide HeLa S3 0.2–8.5 µM − MCF-7 0.2–2.7 µM 
ALL - 
Chaetomium globosum 
[184] 
P. discolor [1] 
P. expansum [1] 
Chaetoglobosin B 
[193] 
Mixed 
biosynthetic 
origin 
BC 3.0 µM 
+ [56,186] 
Chaetomium globosum 
[184] 
P. discolor [1] 
P. expansum [1] 
Chaetoglobosin D 
[193] 
Mixed 
biosynthetic 
origin 
KKU-100 3.4 µM 
KKU-OCA17 12.2 µM 
Chaetomium globosum 
[184] 
P. discolor [1] 
P. expansum [1] 
Chaetoglobosin U 
[194] 
Mixed 
biosynthetic 
origin 
KB 16.0 µM 
Chaetomium globosum 
[184] 
P. discolor [1] 
P. expansum [1] 
Chaetoglobosin X 
[195] 
Mixed 
biosynthetic 
origin 
H-22 7.5 µM 
Chaetomium globosum [57–
61,63,64] 
T. pinophilus [1] 
11-epichaetomugilin I 
[62] 
Polyketide P-388 0.7 pM 
+ [56] HL-60 1.0 pM 
L-1210 1.6 pM 
KB 1.2 pM 
P. chrysogenum [74] 
P. rubens [73] 
(P. terrestre [76]) 
Chloctanspirone A 
[76] 
Polyketide HL-60 9.2 µM − A-549 39.7 µM 
P. buchwaldii [96] 
P. marinum [1] 
P. expansum [204] 
P. rivulorum [205] 
Communesin B 
[206,207] 
Mixed 
biosynthetic 
origin 
P-388 0.5 µg/mL (ED50) − U-937 10.4 µg/mL (ED50) 
THP-1 11.4 µg/mL (ED50) 
NAMALWA 9.9 µg/mL (ED50) 
MOLT-3 8.1 µg/mL (ED50) 
SUP-B15 7.2 µg/mL (ED50) 
Mariannaea elegans 
(Spicaria elegans [192]) 
A. clavatus [190] 
A. rhizopodus [90] 
Hypoxylon terricola [187] 
Cytochalasin E 
[191,192] 
Mixed 
biosynthetic 
origin 
A-2780 0.02 µg/mL (IC100) + [185] HCT-116 1.0 µg/mL (IC100) 
SW-620 0.2 µg/mL (IC100) 
A-549 0.006 µM 
P-388 0.09 µM 
A. striatus (Emericella 
striata [128]) 
Cladorrhinum sp. 
Emestrin A [129] NPR HL-60 83.5 nM 
+ [127] 
A. striatus (Emericella 
striata [128]) 
Cladorrhinum sp. 
Emestrin C [130] NPR DU-145 9.3 nM 
Penicillium sp. BCC 17468 
[147] 
Fudecadione A [147] Terpene MCF-7 12.6 µg/mL − KB 22.3 µg/mL 
NCI-H187 24.9 µg/mL 
A. fumigatus [208] 
P. scabrosum [209] 
Fumagillin [210] Mixed 
biosynthetic 
origin 
Angiogenesis 
inhibitor 
- − 
 TNP-470 [210–214] Synthetic PC-3 - 
MDA-MB-231 - 
Penicillium sp. [215] Linerin [215] Mixed 
biosynthetic 
origin 
POS1 117 nM 
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Table 1. Cont. 
Species (original 
published) Compound Type Target cell IC50 Anti-fungal (+/−) 
A. fumigatus [101,102] 
A. fischeri [103] 
Fumitremorgin C 
[111,113,114] 
NPR P-388 3.9 µg/mL 
(ED50) 
+ [224] 
A. fumigatus [101,102] 
A. fischeri [103] 
12,13-
dehydroxyfumitremor
gin C [112] 
NPR U-937 1.8 µM 
PC-3 6.6 µM 
A. fumigatus [122] 
D. cejpii [123] 
Gliotoxin 
[112,125,126] 
NPR MCF-7 985 nM + [124] 
T47D 365 nM 
BT-474 102 nM 
ZR75-1 158 nM 
MDA MB231 38 nM 
MDA MB435 87 nM 
U-937 0.2 µM 
PC-3 0.4 µM 
P. griseofulvum [225] Griseofulvin  
[2–4,226,227] 
Polyketide HeLa 20 µM + [226,228] 
SCC-114 35 µM 
 GF-15 [5] Synthetic SCC-114 0.9 µM 
Hypocrella bambusae 
(Shiraia bambusicola 
[84,85]) 
Hypocrellin D [85] Polyketide Bel-7721 1.8 µg/mL + [229] 
A-549 8.8 µg/mL 
Anip-973 38.4 µg/mL 
 Synthetic analog [86] Synthetic MCF-7 (PDT) - 
Purpureocillium 
lilacinum[133] 
(P. lilacinum [132]) 
Leucinostatin A 
[132,135–138] 
NPR Ehrlich 1.6 mg/kg (LD50) + [132,134] 
L-1210 410.3 nM (IC100) 
BT-20 2.3 nM 
MCF-7 4 nM 
G-361 7 nM 
HT-144 6 nM 
A-549 16 nM 
A-427 59 nM 
SK-MES-1 12 µM 
Caov-3 17 nM 
Caov-4 53 nM 
SKOV-3 1,236 nM 
HT-29 119 nM 
LoVo 114 nM 
HEp-2 40 nM 
HL-60 12 nM 
HSB-2 5 nM 
K-562 6 nM 
KG-1 46 nM 
RPMI-1788 158 nM 
SKW-6.4 6 nM 
U-937 319 nM 
Raji 11 nM 
A. parasiticus [65,66] 
A. nidulans [67,68] 
Norsolorinic acid 
[67,68] 
Polyketide T-24 10.5 µM − 
MCF-7 12.7 µM 
A. amoenus [115] Notoamides [116,230] NPR HeLa/L-1210 22–52 µg/mL − 
Bipolaris sp.[169,170] 
A. calidoustus [69] 
A. insuetus [69] 
A. keveii [69] 
(A. ustus [171]) 
Sarocladium oryzae [173] 
(Cephalosporium caerulens 
[172]) 
D. maydis [174] 
D. sorghicola [174] 
Ophiobolin A 
[175,176] 
Terpene A-549 0.1 µM + [180,181] 
HT-29 0.1 µM 
Mel-20 0.1 µM 
P-388 0.06 µM 
OVCAR-3 0.3 µM 
Bipolaris oryzae [179] 3-anhydro-6-
hydroxyophiobolin A 
[179] 
Terpene HepG2 6.5 µM 
K-562 4.1 µM 
Aspergillus section Usti [69] 
(A. ustus [177]) 
Ophiobolin O 
[177,178] 
Terpene MFC-7 17.9 µM 
P-388 4.7 µM 
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Table 1. Cont. 
Species (original 
published) 
Compound Type Target cell IC50 Anti-fungal (+/−) 
Talaromyces sp. 
(Penicillium sp.) [199] 
Penicidone B [199] Mixed 
biosynthetic 
origin 
SW1116 54.2 µM − 
K-562 21.1 µM 
KB 29.6 µM 
HeLa 35.2 µM 
Penicillium sp. [200] 
Auxarthron reticulatum 
[201] 
Penicinoline [202] Mixed 
biosynthetic 
origin 
HepG2 13.2 µM − 
Penicillium sp. [200] 
Auxarthron reticulatum 
[201] 
Methyl-penicinoline 
[202] 
Mixed 
biosynthetic 
origin 
HepG2 11.3 µM 
T. pinophilus [1] 
(P. simplicissimum [54]) 
Penisimplicissin [55] Polyketide HL-60 −6.7 (log10 GI50) − 
CCRF-CEM −5.8 (log10 GI50) 
Phaeosphaeria sp. [87] Phaeosphaerin B [87] Polyketide PC-3 2.4 µM − 
DU-145 9.5 µM 
LNCaP 2.7 µM 
A. ustus [117] Phenylahistin [118] NPR A-431 0.22 µM − 
A-549 0.30 µM 
HeLa 0.20 µM 
K-562 0.19 µM 
P-388 0.33 µM 
MCF-7 3.7 µM 
TE-671 0.18 µM 
A. taichungensis [79] Prenylterphenyllin A 
[79] 
Polyketide A-549 8.3 µM − 
HL-60 1.5 µM 
A. candidus [77,78] 4”-deoxyisoterprenin 
[78] 
Polyketide KB3-1 6.2 µM 
A. taichungensis [79] Prenylcandidusin B 
[79] 
Polyketide P-388 1.6 µM 
Pseudeurotium ovalis [196] 
A. fumigatus [197] 
Pseurotin D [198] Mixed 
biosynthetic 
origin 
MFC-7 15.6 µM − 
T. purpurogenus mutant 
BD-1-6 [1] 
(P. purpurogenum [216]) 
Purpurogemutantidin 
[216] 
Mixed 
biosynthetic 
origin 
K-562 0.9 µM + [217] 
HeLa 16.6 µM 
BGC-823 31.0 µM 
MCF-7 26.3 µM 
T. purpurogenus mutant 
BD-1-6 [1] 
(P. purpurogenum [216]) 
Macrophorin A [216] Mixed 
biosynthetic 
origin 
HL-60 0.9 µM 
A. parasiticus [231] Sequoiamonascin A 
[231] 
Polyketide MCF-7 1% − 
NCI-H460 1% 
SF-268 2% 
 Percent cell 
growth compared 
to untreated cells 
at 10 µM 
P. solitum [20,25] 
(P. brevicompactum [18]) 
P. hirsutum [20] 
(P. citrinum [19]) 
Compactin [28] Polyketide AML 2.6 µM (IC100) + [18] 
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Table 1. Cont. 
Species (original 
published) Compound Type Target cell IC50 Anti-fungal (+/−) 
A. terreus [26] 
Monascus sp.[27] 
Lovastatin [29–32] Polyketide OVHS-1 39 µM 
+ [22–24] Calu-1 3 µM 
H-460 3 µM 
A-549 10 µM 
H-441 30 µM 
Ovca-432 2 µM 
A-2780 3 µM 
Hey 3 µM 
Ovca-429 5 µM 
HOC-7 10 µM 
DOV-13 11 µM 
Skov-3 21 µM 
A-2780-ADR 21 µM 
A-2780-CIS 22 µM 
MCF-7 1.7 µM 
HepG2 2.7 µM 
HeLa 1.5 µM 
AML - 
 Simvastatin 
[1,20,29,33,34] 
Synthetic DLRP 0.9 µM 
+ [23,24] H-1299 1.3 µM 
HT-144 1.0 µM 
MI-14 0.8 µM 
SK-MEL-28 0.8 µM 
BT-474A 4.2 µM 
SKBR-3 2.2 µM 
MDA-MB-453 5.4 µM 
BT-20 1.7 µM 
AML - 
A. ochraceus [106] 
A. westerdijkiae [107] 
Stephacidin B [106] NPR PC-3 0.4 µM − 
LNCaP 0.06 µM 
A-2780 0.3 µM 
A-2780/DDP 0.4 µM 
A-2780/Tax 0.3 µM 
HCT-116 0.5 µM 
HCT-116/mdr+ 0.5 µM 
HCT-116/topo 0.4 µM 
MCF-7 0.3 µM 
SKBR-3 0.3 µM 
LX-1 0.4 µM 
Taxomyces andreanea [140] 
P. raistrickii [141] 
Taxol [139,142–145] Terpene Clinical use: 
Ovarian tumors 
Breast tumors 
Lung tumors 
Kaposi’s sarcoma 
- + [146] 
A. terreus [148] Terrecyclic acid A 
[148,149,232] 
Terpene NCI-H460 10.6 µM + [148] 
MCF-7 24.1 µM 
SF-268 14.7 µM 
P-388 63–125 mg/kg 
(LD50) 
A. terreus [37] Terrein [38] Polyketide MCF-7 1.1 nM + [36] 
PANC-1 9.8 µM 
HepG2 66.8 µM 
Fusarium spp. [151] 
Isaria japonica [157] 
4-Acetyl-12,13-epoxy-
9-trichothecene- 3,15-
diol (AETD) [157] 
Terpene HL-60 10 nM + [154] 
U-937 22 nM 
HeLa 45 nM 
MCF-7 53 nM 
Hep-G2 170 nM 
Fusarium spp. [151] 
Myrothecium roridum [158] 
12’hydroxyroridin E 
[158] 
Terpene L-1210 0.2 µM 
BC-1 0.9 µM 
NCI-H187 1.5 µM 
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Table 1. Cont. 
Species (original 
published) Compound Type Target cell IC50 Anti-fungal (+/−) 
P. citrinum [80] Tricitrinol B [80] Polyketide HL-60 3.2 µM − 
HCT-116 4.8 µM 
KB 3.9 µM 
A. fumigatus 
[104,105,108,109] 
Ds2-tryprostatin B 
[108] 
NPR NCI-H-522 15.8 µM (GI50) − 
MCF-7 15.9 µM (GI50) 
PC-3 11.9 µM (GI50) 
A. fumigatus 
[104,105,108,109] 
18-oxotryprostatin A 
[110] 
NPR A-549 1.3 µM 
A. fumigatus 
[104,105,108,109] 
Spirotryprostatin E 
[109] 
NPR MOLT-4 3.1 µM 
HL-60 2.3 µM 
A-549 3.1 µM 
Penicillium sp. [150] Unnamed chloro-
trinoreremophilane 
sesquiterpene [150] 
Terpene HL-60 11.8 µM − 
A-549 12.2 µM 
A. wentii [160] Wentilactones [161] Terpene SMMC-7721 19 µM + [233] 
T. wortmannii [1] 
(P. wortmannii [162]) 
Or similar species. 
Wortmannin  
[163–168] 
Terpene HL-60 30 nM + [162] 
K-562 25 nM 
KNS-62 100–200 nM 
Colo-699 100–200 nM 
P. chrysogenum [1] 
D. cejpii [90] 
(D. albus[90]) 
Xanthocillin X 
[89,91,92] 
NPR Ehrlich ascites 
carcinoma-mouse 
strain 
40 mg/kg (LD50) + [89] 
K-562 0.4 µg/mL 
HeLa 1.2 µg/mL 
MCF-7 12 µg/mL 
HepG2 7 µg/mL 
NCI-H460 10 µg/mL 
Du-145 8 µg/mL 
MDA-MB-231 8 µg/mL 
Aspergillus sp. [93] BU-4704 [93] NPR HCT-116 0.6 µg/mL 
B16-F10 4.3 µg/mL 
P. chrysogenum [1] Xanthocillin X  
di-methoxy [94] 
NPR HepG2 0.2 µg/mL 
MCF-7 0.4 µg/mL 
KB 0.4 µg/mL 
6. Conclusions  
In this article we have reviewed 50 compounds or compound families with anticancer and often also 
antifungal activities, primarily produced by Aspergillus, Penicillium and Talaromyces. Mycologists 
predict that less than 10% of all fungal species have been isolated so far, indicating a huge potential for 
further discovery of novel bioactive chemical scaffolds, if these fungi can be cultured in the laboratory. 
New strategies such as the application of epigenetic modifiers may help to uncover the full 
biosynthetic potential of fungi and other microorganisms. Development and improvement of screening 
methods and assays will further assist revealing new bioactivities of already known compounds. 
Additionally, ongoing progress in fast dereplication, including improvement of the performance of 
mass spectrometers and high resolution of UHPLC chromatograms, will ensure that database searches 
will lead to fewer possible candidates thereby advancing the drug discovery process. Altogether the 
future seems promising for discovery of many more bioactive small molecules to be used either as 
scaffolds for: (i) diversity oriented synthesis, or (ii) as a starting point for cloning and engineering of 
whole biosynthetic gene clusters towards novel engineered bioactive natural products. 
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